Eurofins Launches Second Buy-Back Programme of Its Own Shares
21 10월 2023 - 12:45AM
Business Wire
Regulatory News:
Eurofins Scientific SE (the “Company”) (EUFI.PA) (Paris:ERF)
announces its intention to launch a new buy-back programme of its
own shares (ISIN FR0014000MR3) for a maximum amount representing up
to 2% of its share capital. This second programme follows the first
programme that took place between 3 October 2022 and 8 August 2023.
The new programme would begin on 25 October 2023 and last until 24
October 2025, subject to the renewal of the authorisation of such
share repurchase programme by the Annual General Meeting (AGM) of
the Company to be held in April 2024. The Company may at any time
interrupt this programme in view of market conditions and/or the
evolution of its investment strategy.
The shares to be purchased under this programme will be
primarily used to hedge the Company’s Long-Term Incentive plans but
may also be cancelled, used to partially finance acquisitions or
for other purposes approved by the Board of Directors and within
the authorization of the EGM.
The Company is mandating an independent provider of financial
services to execute the first tranche of this programme for a
maximum duration of three months starting on 25 October 2023 and
ending on 24 January 2024 with a maximum volume of one million
shares or 0.52% of its share capital. The exact quantum and purpose
allocation of the bought-back shares will be communicated at the
end of this first tranche.
Over the course of the first share buy-back programme that took
place between 3 October 2022 and 8 August 2023, 1,121,493 shares
were repurchased, representing 0.58% of the current share capital.
As of 30 September 2023, 253,515 shares were used and delivered to
the benefit of holders of the Company’s Long-Term Incentive
instruments (upon exercise of Stock Options or vesting of
Restricted Stock Units (RSUs)).
Notes to Editors:
For more information, please visit www.eurofins.com
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. The Eurofins network of companies
believes that it is the global leader in food, environment,
pharmaceutical and cosmetic product testing and in discovery
pharmacology, forensics, advanced material sciences and agroscience
contract research services. It is also one of the market leaders in
certain testing and laboratory services for genomics, and in the
support of clinical studies, as well as in biopharma contract
development and manufacturing. It also has a rapidly developing
presence in highly specialised and molecular clinical diagnostic
testing and in-vitro diagnostic products.
With over 62,000 staff across a decentralised and
entrepreneurial network of ca. 900 laboratories in 61 countries,
Eurofins offers a portfolio of over 200,000 analytical methods to
evaluate the safety, identity, composition, authenticity, origin,
traceability and purity of a wide range of products, as well as
providing innovative clinical diagnostic testing services and
in-vitro diagnostic products.
Eurofins companies’ broad range of services are important for
the health and safety of people and our planet. The ongoing
investment to become fully digital and maintain the best network of
state-of-the-art laboratories and equipment supports our objective
to provide our customers with high-quality services, innovative
solutions and accurate results in the best possible turnaround time
(TAT). Eurofins companies are well positioned to support clients’
increasingly stringent quality and safety standards and the
increasing demands of regulatory authorities as well as the
evolving requirements of healthcare practitioners around the
world.
Eurofins has grown very strongly since its inception and its
strategy is to continue expanding its technology portfolio and its
geographic reach. Through R&D and acquisitions, the Group draws
on the latest developments in the field of biotechnology and
analytical chemistry to offer its clients unique analytical
solutions.
Shares in Eurofins Scientific are listed on the Euronext Paris
Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF
FP).
Until it has been lawfully made public widely by Eurofins
through approved distribution channels, this document contains
inside information for the purpose of Regulation (EU) 596/2014 of
the European Parliament and of the Council of 16 April 2014 on
market abuse, as amended.
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgment of
Eurofins Scientific’s management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantees can be made as to their completeness
or validity.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231020789382/en/
Investor Relations Eurofins Scientific SE Phone: +32 2 766 1620
E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Enerplus (NYSE:ERF)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024